Menu

DJ Merck and Bristol-Myers Squibb Are Seeing Rising Sales of Their Cancer Drugs –

0 Comment

DJ Merck and Bristol-Myers Squibb Are Seeing Rising Sales of Their Cancer Drugs — Barrons.com

By Bill Alpert

Two leaders in the war against cancer reported September quarter earnings Thursday 早上。 Investors like Bristol-Myers Squibb and Merck & Co. for their growing sales of immune-oncology drugs: 布里斯托尔 Opdivo and Merck”s Keytruda. Anyone with a rooting interest against cancer should care, too, as these companies find new tumor targets for these so-called I-O treatments, which recruit our immune system to fight 去核。

In the September quarter, Merck raced into the lead for I-O 推销术。 Its Keytruda revenue jumped more than 80% in the quarter, to $1.9 一万亿。 “Our innovation strategy is working,” Chief Executive Ken Frazier said in a conference 呼唤。 “This drug continues to lead the I-O field with its breadth and depth against multiple tumor types.”

“Keytruda is now the leading I-O product,” added Adam Schechter, the 公司的 president of global human health.

In premarket trading Thursday morning, Merck stock was off , to $ per share, while Bristol-Myers Squibb stock was up , to $ per 分享。

Merck”s vaccine products also had a strong quarter, with $2.2 billion in sales, thanks to 55% growth for the Gardasil vaccine, which protects against cervical and other cancers caused by the HPV 病毒。

Overall, Merck reported total revenue of $10.8 billion in the quarter, up 5% from the 年终 $10.3 一万亿。 Profits were $3.2 billion, or $ per share share (看轻) restructuring charges that reduced earnings to 73 cents, under generally-accepted accounting 准绳(准绳) So earnings rose 7% above the non-GAAP $ per share reported in the September 2017 刻。

Merck”s just-reported results modestly beat the consensus forecast (AS) tallied by FactSet) for non-GAAP earnings of $3 billion, or $ per 分享。 That success encouraged the company to nudge up its guidance for 2018”s non-GAAP earnings to about $ a share, from prior guidance for $. The company also boosted its dividend by 15%, to $ a year, and add $10 billion to its existing buyback program for its 去市场买东西占有率。

Bristol announced quarterly sales of Opdivo of $1.8 billion, up 42% from the 年终 $1.3 一万亿。 Sales of the 公司的 血液稀释剂 product Eliquis — a safer alternative to the traditional drug warfarin — grew 28% to $1.6 一万亿。

While Bristol launched the immune-oncology field with its Yervoy drug for the skin cancer melanoma, Merck established its combination of Keytruda and chemotherapy as a first-line treatment in lung cancer, a bigger market for cancer 药物。 A clinical trial of 布里斯托尔 treatment for lung cancer hasn”t produced compelling results, disheartening the 公司的 扬去。

Overall, 布里斯托尔 revenue for the quarter was $5.7 billion, compared with $5.2 billion a year 初期的。 Earnings were $1.8 billion or $1.09 cents per share share (看轻) certain GAAP 费), compared with $1.2 billion a year earlier, per 75 cents a 分享。 The FactSet consensus forecast had looked for non-GAAP earnings of $1.5 billion, or 91 cents per share, on revenue of $5.7 一万亿。 The company upped its guidance for the 2018 年 non-GAAP earnings to about $ per share, from $.

Investors trade both stocks based on long-term expectations for the 公司的 cancer 药物。 Through Wednesday, Bristol-Myers Squibb stock (去市场买东西占有率行情) BMY) had fallen 19% in 2018, to $ per share, while Merck stock (MRK) had risen 26%, to $ per 分享。

(完毕) Dow Jones Newswires

October 25, 2018 09:25 ET (13:25 格林威治镇规范时期)

Copyright (c) 2018 Dow Jones & Company, Inc.

DJ。默克公司和布里斯托尔梅尔斯Squb公司的抗癌药物经销正升起。

啤酒西装背心用的怀表链条

两位抗击巨蟹宫的引航员在菊月宣告了他们的进项。。包围者如布里斯托尔迈尔斯、石贵宝与默克公司。因他们的豁免去核药物经销不休增长。:布里斯托尔的Opdio和默克的KiTruta。诸如此类对巨蟹宫有十分趣味的人也必不可少的事物关怀。,因这些公司为这些相同的的i-O找到了新的去核靶点。,这些处理新学生了we的所有格形式的豁免系统来对立去核。。

9一个人月的时间,默克公司(MiCK)在IO经销中占领导致位置。。该公司的KiTruta进项在本地区升起了80%在上的。,高达19亿一元纸币。。we的所有格形式的开创战术正起作用。,首席执行官KenFrazier在电信会议上说。。这种药物以其广大地域和吃水持续导致于IO担任守队队员。,抗多种去核典型。”

KiTruta如今是导致的IO制作。,”该公司全球人类康健董事长亚当·谢克特(AdamSechhter)粮食道。

在周四午前的买卖中。,默克股价下跌,每股一元纸币,而布里斯托-迈尔斯施贵宝(Bristol-MyersSquibb)股价下跌,每股一元纸币。

默克公司的疫苗制作也举起微弱的表示。,经销额达22亿一元纸币。,这是因疫苗的增长了55%。,该疫苗可以引领宫颈癌和安宁由HPV病毒导致的巨蟹宫。。

总体就,默克公司本地区的总进项为108亿一元纸币。,去年同一时期增长5%至1030亿一元纸币。回转是32亿一元纸币。,或每股一元纸币(除重组费),鉴于公认会计工作准绳,重组本钱使变弱了73百。。依据,其进项比2017年9月发布的每股一元纸币的非公认会计工作准则(non-GAAP)增长了7%。

默克公司的公报略高于普通认为会发生(计算),非GAAP回转为30亿一元纸币。,那是每股一元纸币。。这一成冲动行事的水蒸气该公司将2018年非公认会计工作准则(non-GAAP)进项认为会发生从优于的一元纸币上调每股一元纸币摆布。该公司还将股息繁殖了15%。,每年实现一元纸币,并为持续存在的去市场买东西占有率回购放映累积而成了100亿一元纸币。

布里斯托尔宣告,OPDIO地区经销额达18亿一元纸币。,同比增长42%—130亿。该公司的血液稀释剂-更保险柜的顶替经外传说药物华法令阻凝剂的制作-的经销额增长了28%,高达16亿一元纸币。。

布里斯托尔卖得Ye M Woy药物药物皮肤胎记瘤,同时,默克公司助手KiTruta和化疗作为一线药物。,这是一个人更大的巨蟹宫药物去市场买东西。。布里斯托尔肺癌的临床试验还没有发生令人信服的R。,公司的扬去查明灰心。。

整个就,布里斯的地区进项为57亿一元纸币。,去年同一时期为52亿一元纸币。。回转为18亿一元纸币或每股亿一元纸币(要不是某个GAAP费),一年前,它是12亿一元纸币。,每股75百。FACSET共识预测认为会发生,非GAAP进项为15亿一元纸币。,这是每股91百。,进项是57亿一元纸币。。该公司将2018年非公认会计工作准则进项的认为会发生从一元纸币上调每股一元纸币。

包围者主要成分他们的一世纪一次的认为会发生买卖这两种去市场买东西占有率。。短暂拜访星期三,布里斯托尔迈尔斯爆管(布里斯托尔梅尔斯) 斯奎布)2018的去市场买东西占有率下跌了19%。,每股一元纸币,默克(Melk)股价下跌26%,每股一元纸币。

(完)道琼斯琼斯通讯社

October 25, 2018 09:25 ET (13:25 格林威治镇规范时期)

保留一切权力(C)道琼斯公司2018

发表评论

电子邮件地址不会被公开。 必填项已用*标注